Erste Asset Management’s ImmunityBio IBRX Stock Holding History

Erste Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-153,000	Closed	-$312K	–	629
2025 Q4	$312K	Hold	153,000	–	–	﹤0.01%	537
2025 Q3	$393K	Hold	153,000	–	–	﹤0.01%	505
2025 Q2	$413K	Hold	153,000	–	–	﹤0.01%	659
2025 Q1	$480K	Hold	153,000	–	–	0.01%	434
2024 Q4	$425K	Hold	153,000	–	–	0.01%	451
2024 Q3	$601K	Hold	153,000	–	–	0.01%	420
2024 Q2	$1M	Hold	153,000	–	–	0.01%	372
2024 Q1	$835K	Hold	153,000	–	–	0.01%	380
2023 Q4	$797K	Buy	+153,000	New	+$480K	0.01%	391

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Erste Asset Management's IBRX Position: Q1 2026 in Review

Erste Asset Management sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 153,000 shares — an estimated $312K sold.

Erste Asset Management first reported a position in IBRX in Q4 2023 and held it in 9 quarters. The position peaked at $1M in Q2 2024. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Erste Asset Management reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
Erste Asset Management sold 153,000 ImmunityBio shares in Q1 2026, an estimated $312K.
Erste Asset Management first reported a position in ImmunityBio in Q4 2023 and held it in 9 quarters.
Erste Asset Management's ImmunityBio position peaked at $1M in Q2 2024.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Erste Asset Management's 13F filing for Q1 2026, filed 11 May 2026.